Cited by 185Schizophrenia research and treatmentMental Health and PsychiatryNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

Open access

Théberge, Jean, Williamson, Kate E., Aoyama, Naoko, Drost, Dick J., Manchanda, Rahul, Malla, Ashok K., Northcott, Sandra, Menon, Ravi S., Neufeld, Richard W. J., Rajakumar, Nagalingam, Pavlosky, William, Densmore, Maria, Schaefer, Betsy, Williamson, Peter C.·2007·British Journal of Psychiatry

DOI 10.1192/bjp.bp.106.033670

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Progressive volumetric changes in the brains of people with schizophrenia have been attributed to a number of factors. AIMS: To determine whether glutamatergic changes in patients with schizophrenia correlated with grey-matter losses during the first years of illness. METHOD: Left anterior cingulate and thalamic glutamatergic metabolite levels and grey-matter volumes were examined in 16 patients with first-episode schizophrenia before and after 10 months and 30 months of antipsychotic treatment and in 16 healthy participants on two occasions 30 months apart. RESULTS: Higher than normal glutamine levels were found in the anterior cingulate and thalamus of never-treated patients. Thalamic levels of glutamine were significantly reduced after 30 months. Limited grey-matter reductions were seen in patients at 10 months followed by widespread grey-matter loss at 30 months. Parietal and temporal lobe grey-matter loss was correlated with thalamic glutamine loss. CONCLUSIONS: Elevated glutamine levels in never-treated patients followed by decreased thalamic glutamine and grey-matter loss in connected regions could indicate either neurodegeneration or a plastic response to reduced subcortical activity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1192/bjp.bp.106.033670

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Applied Multivariate Statistics for the Social Sciences
Stevens, J. P. (2012) · Routledge eBooks · doi:10.4324/9780203843130 · Cited by 10,652
Voxel-Based Morphometry—The Methods
Ashburner, J., & Friston, K. J. (2000) · NeuroImage · doi:10.1006/nimg.2000.0582 · Cited by 8,676
Structured Clinical Interview for DSM-IV Axis I Disorders
Spitzer, R. L., First, M. B., & Gibbon, M. (1997) · Medical Entomology and Zoology · Cited by 3,582
Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet
First, M. B., Spitzer, R. L., Gibbon, M., & Williams, J. B. W. (1997) · American Psychiatric Press eBooks · Cited by 3,101
Scale for the Assessment of Negative Symptoms (SANS)*
(1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000291502 · Cited by 2,710
Scale for Assessment of Positive Symptoms (SAPS) 1984
Andreasen, N. C. (1995) · Open Scholarship Institutional Repository (Washington University in St. Louis) · Cited by 2,423
Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions.
Alexander, G. E., Crutcher, M. D., & DeLong, M. R. (1990) · PubMed · Cited by 2,422
A review of MRI findings in schizophrenia
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00163-3 · Cited by 2,346
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,056
Chapter 6 Basal ganglia-thalamocortical circuits: Parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions
(1991) · Progress in Brain Research · doi:10.1016/s0079-6123(08)62678-3 · Cited by 1,961

Flagged first, then by citations

Show all 42 references

Sorted by citations

Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies
Marsman, A., van den Heuvel, M. P., Klomp, D. W. J., Kahn, R. S., Luijten, P. R., & Hulshoff Pol, H. E. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr069 · Cited by 457
Nature of Glutamate Alterations in Schizophrenia: A Meta-analysis of Proton Magnetic Resonance Spectroscopy Studies
Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
A systematic review of the effects of antipsychotic drugs on brain volume
Moncrieff, J., & Leo, J. (2010) · Psychological Medicine · doi:10.1017/s0033291709992297 · Cited by 312
Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy
Mao, X. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1519 · Cited by 296
Abnormal Glutamatergic Neurotransmission and Neuronal-Glial Interactions in Acute Mania
Öngür, D., Jensen, J. E., Prescot, A. P., Stork, C., Lundy, M. Y., Cohen, B. M., & Renshaw, P. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.05.014 · Cited by 272
Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis
de la Fuente‐Sandoval, C., León-Ortíz, P., Favila, R., Stephano, S., Mamo, D. C., Ramírez‐Bermúdez, J., & Graff‐Guerrero, A. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.65 · Cited by 235
Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume
Stone, J. M., Day, F., Tsagaraki, H., Valli, I., McLean, M. A., Lythgoe, D. J., O'Gorman, R. L., Barker, G. J., & McGuire, P. K. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.05.006 · Cited by 231
Treatment-Resistant Schizophrenia Patients Show Elevated Anterior Cingulate Cortex Glutamate Compared to Treatment-Responsive
Mouchlianitis, E. D., Bloomfield, M., Law, V., Beck, K., Selvaraj, S., Rasquinha, N., Waldman, A. D., Turkheimer, F., Egerton, A., Stone, J. M., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv151 · Cited by 226
The neurobiology and treatment of first-episode schizophrenia
Kahn, R. S., & Sommer, I. E. (2015) · Molecular Psychiatry · doi:10.1038/mp.2014.66 · Cited by 219
Schizophrenia and Alterations in Self-experience: A Comparison of 6 Perspectives
Lysaker, P. H., & Lysaker, J. T. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn077 · Cited by 230
Imaging glutamate in schizophrenia: review of findings and implications for drug discovery
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Slifstein, M., Javitt, D. C., Lieberman, J. A., Abi-Dargham, A., & Girgis, R. R. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.136 · Cited by 205
Neurometabolites in schizophrenia and bipolar disorder — A systematic review and meta-analysis
Kraguljac, N. V., Reid, M. A., White, D. M., Jones, R., den Hollander, J., Lowman, D., & Lahti, A. C. (2012) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2012.02.003 · Cited by 207
Meta-Analysis of the Efficacy of Adjunctive NMDA Receptor Modulators in Chronic Schizophrenia
Singh, S. P., & Singh, V. (2011) · CNS Drugs · doi:10.2165/11586650-000000000-00000 · Cited by 194
Increased Hippocampal Glutamate and Volumetric Deficits in Unmedicated Patients With Schizophrenia
Kraguljac, N. V., White, D. M., Reid, M. A., & Lahti, A. C. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2437 · Cited by 191
Creatine abnormalities in schizophrenia and bipolar disorder
Öngür, D., Prescot, A. P., Jensen, J. E., Cohen, B. M., & Renshaw, P. F. (2009) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2008.06.002 · Cited by 190
Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy
Bernstein, H., Steiner, J. H., & Bogerts, B. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.59 · Cited by 192
Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change
Anticevic, A., Hu, X., Xiao, Y., Hu, J., Li, F., Bi, F., Cole, M. W., Savic, A., Yang, G. J., Repovs, G., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2310-14.2015 · Cited by 178
Anterior Cingulate Glutamate Levels Related to Clinical Status Following Treatment in First-Episode Schizophrenia
Egerton, A., Brugger, S. P., Raffin, M., Barker, G. J., Lythgoe, D. J., McGuire, P. K., & Stone, J. M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.113 · Cited by 168
Translating the MAM model of psychosis to humans
Modinos, G., Allen, P., Grace, A. A., & McGuire, P. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.12.005 · Cited by 165
“Longitudinal MRS studies could help to resolve this issue, but there are few such studies in the literature [61, 97].”
BackgroundResult
Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis
Wang, A. M., Pradhan, S., Coughlin, J. M., Trivedi, A. M., DuBois, S. L., Crawford, J. L., Sedlak, T. W., Nucifora, F. C., Nestadt, G., Nucifora, L. G., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3637 · Cited by 161
Glutamatergic abnormalities in schizophrenia: A review of proton MRS findings
Poels, E. M. P., Kegeles, L. S., Kantrowitz, J. T., Javitt, D. C., Lieberman, J. A., Abi‐Dargham, A., & Girgis, R. R. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2013.12.013 · Cited by 158
The Longitudinal Course of Schizophrenia Across the Lifespan
Heilbronner, U., Samara, M. T., Leucht, S., Falkai, P., & Schulze, T. G. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000092 · Cited by 157
1H-MRS at 4 Tesla in minimally treated early schizophrenia
Bustillo, J. R., Rowland, L. M., Mullins, P., Jung, R., Chen, H., Qualls, C., Hammond, R., Brooks, W. M., & Lauriello, J. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.121 · Cited by 153
Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis
Torres, U. S., Portela-Oliveira, E., Borgwardt, S., & Busatto, G. F. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-342 · Cited by 147
Glutamate-mediated excitotoxicity in schizophrenia: A review
Plitman, E., Nakajima, S., de la Fuente‐Sandoval, C., Gerretsen, P., Chakravarty, M. M., Kobylianskii, J., Chung, J. K., Caravaggio, F., Iwata, Y., Remington, G. J., et al. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.07.015 · Cited by 150
Longitudinal loss of gray matter volume in patients with first-episode schizophrenia: DARTEL automated analysis and ROI validation
Asami, T., Sylvain Bouix, A., Whitford, T. J., Shenton, M. E., Salisbury, D. F., & McCarley, R. W. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.08.066 · Cited by 147
Association of Age, Antipsychotic Medication, and Symptom Severity in Schizophrenia With Proton Magnetic Resonance Spectroscopy Brain Glutamate Level
Merritt, K., McGuire, P. K., Egerton, A., 1H-MRS in Schizophrenia Investigators, Aleman, A., Block, W., Bloemen, O., Borgan, F., Bustillo, J., Capizzano, A. A., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2021.0380 · Cited by 142
Self-citation
Thalamic Pathology in Schizophrenia
Cronenwett, W. J., & Csernansky, J. G. (2010) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_55 · Cited by 140
Longitudinal MRI study of cortical thickness, perfusion, and metabolite levels in major depressive disorder
Järnum, H., Eskildsen, S. F., Steffensen, E. G., Lundbye‐Christensen, S., Simonsen, C. W., Thomsen, I. S., Fründ, T., Théberge, J., & Larsson, E. (2011) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2011.01766.x · Cited by 142
Self-citation
Proton Magnetic Resonance Spectroscopy and Illness Stage in Schizophrenia—A Systematic Review and Meta-Analysis
Brugger, S., Davis, J. M., Leucht, S., & Stone, J. M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.10.004 · Cited by 131
Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre 1H-MRS study (OPTiMiSE)
Egerton, A., Broberg, B. V., van Haren, N. E. M., Merritt, K., Barker, G. J., Lythgoe, D. J., Pérez‐Iglesias, R., Baandrup, L., Düring, S. W., Sendt, K.-V., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0082-9 · Cited by 127
Assessments of Function and Biochemistry of the Anterior Cingulate Cortex in Schizophrenia
Reid, M. A., Stoeckel, L. E., White, D. M., Avsar, K. B., Bolding, M., Akella, N. S., Knowlton, R. C., den Hollander, J. A., & Lahti, A. C. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.013 · Cited by 124
Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis.
Fusar-Poli, P., Stone, J., Broome, M., Valli, I., Mechelli, A., McLean, M. A., Lythgoe, D., O'Gorman, R. L., Barker, G. J., & McGuire, P. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.46 · Cited by 114
Reversal of imbalance between kynurenic acid and 3-hydroxykynurenine by antipsychotics in medication-naïve and medication-free schizophrenic patients
Myint, A.-M., Schwarz, M., Verkerk, R. M., Mueller, H. H., Zach, J., Scharpé, S., Steinbusch, H. W. M., Leonard, B. E., & Kim, Y. K. (2011) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2011.05.005 · Cited by 116
7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia
Reid, M. A., Salibi, N., White, D. M., Gawne, T. J., Denney, T. S., & Lahti, A. C. (2017) · Schizophrenia Bulletin · doi:10.1093/schbul/sbx190 · Cited by 106
Glutamatergic Neurometabolites in Clozapine-Responsive and -Resistant Schizophrenia
McIlwain, M., Anderson, V. M., Pillai, A., Kydd, R. R., & Russell, B. R. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu117 · Cited by 104
Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia
Aoyama, N., Théberge, J., Drost, D. J., Manchanda, R., Northcott, S., Neufeld, R. W. J., Menon, R. S., Rajakumar, N., Pavlosky, W. F., Densmore, M., et al. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.079608 · Cited by 105
Self-citation
Utility of Imaging-Based Biomarkers for Glutamate-Targeted Drug Development in Psychotic Disorders: A Randomized Clinical Trial
Javitt, D. C., Carter, C. S., Krystal, J. H., Kantrowitz, J. T., Girgis, R. R., Kegeles, L. S., Ragland, J. D., Maddock, R. J., Lesh, T. A., Tanase, C., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3572 · Cited by 100
Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.
Natsubori, T., Inoue, H., Abe, O., Takano, Y., Iwashiro, N., Aoki, Y., Koike, S., Yahata, N., Katsura, M., Gonoi, W., et al. (2014) · Schizophrenia bulletin · doi:10.1093/schbul/sbt124 · Cited by 110
Relationship between Glutamate Dysfunction and Symptoms and Cognitive Function in Psychosis
Merritt, K., McGuire, P. K., & Egerton, A. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00151 · Cited by 100
The psychoses: Cluster 3 of the proposed meta-structure for DSM-V and ICD-11: Paper 4 of 7 of the thematic section: ‘A proposal for a meta-structure for DSM-V and ICD-11’
Carpenter, W. T., Bustillo, J. R., Thaker, G. K., van Os, J., Krueger, R. F., & Green, M. J. (2009) · Psychological Medicine · doi:10.1017/s0033291709990286 · Cited by 99
Lempel–Ziv complexity in schizophrenia: A MEG study
Fernández, A., López‐Ibor, M., Turrero, A., Santos, J.-M., Morón, M.-D., Hornero, R., Gómez, C., Méndez, M. A., Ortiz, T., & López-Ibor, J. J. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.04.011 · Cited by 87
Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis
Egerton, A., Stone, J., Chaddock, C. A., Barker, G., Bonoldi, I., Howard, R. M., Merritt, K., Allen, P., Howes, O., Murray, R., et al. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.143 · Cited by 94
Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal 1H-MRS Studies
Egerton, A., Bhachu, A., Merritt, K., McQueen, G., Szulc, A., & McGuire, P. K. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00066 · Cited by 84
7T Proton Magnetic Resonance Spectroscopy of Gamma-Aminobutyric Acid, Glutamate, and Glutamine Reveals Altered Concentrations in Patients With Schizophrenia and Healthy Siblings
Thakkar, K. N., Rösler, L., Wijnen, J. P., Boer, V. O., Klomp, D. W. J., Cahn, W., Kahn, R. S., & Neggers, S. F. W. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.04.007 · Cited by 82
Increased Glutamine in Patients Undergoing Long-term Treatment for Schizophrenia
Bustillo, J., Chen, H., Jones, T., Lemke, N. T., Abbott, C., Qualls, C., Cañive, J. M., & Gasparovic, C. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3939 · Cited by 82
In vivo assessment of neurotransmitters and modulators with magnetic resonance spectroscopy: Application to schizophrenia
Wijtenburg, S. A., Yang, S., Fischer, B. A., & Rowland, L. M. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.007 · Cited by 83
Mapping prodromal psychosis: A critical review of neuroimaging studies
Fusar‐Poli, P., McGuire, P. K., & Borgwardt, S. (2011) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.006 · Cited by 75
A prospective longitudinal volumetric MRI study of superior temporal gyrus gray matter and amygdala–hippocampal complex in chronic schizophrenia
Yoshida, T., McCarley, R. W., Nakamura, M., Lee, K., Koo, M.-S., Bouix, S., Salisbury, D. F., Morra, L., Shenton, M. E., & Niznikiewicz, M. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.004 · Cited by 74
Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients
de la Fuente‐Sandoval, C., Reyes-Madrigal, F., Mao, X., León-Ortíz, P., Rodríguez-Mayoral, O., Jung-Cook, H. H., Solís‐Vivanco, R., Graff‐Guerrero, A., & Shungu, D. C. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.09.028 · Cited by 73
Regional gray matter reduction and theory of mind deficit in the early phase of schizophrenia: a voxel‐based morphometric study
Herold, R., Feldmann, Á., Simon, M., Tényi, T., Kövér, F., Nagy, F., Varga, E., & Fekete, S. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01297.x · Cited by 74
Progressive cortical reorganisation: A framework for investigating structural changes in schizophrenia
Palaniyappan, L. K. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.04.028 · Cited by 77
Treatment response after 6 and 26 weeks is related to baseline glutamate and GABA levels in antipsychotic-naïve patients with psychosis
Bojesen, K. B., Ebdrup, B. H., Jessen, K., Sigvard, A. K., Tangmose, K., Edden, R. A. E., Larsson, H. B. W., Rostrup, E., Broberg, B. V., & Glenthoj, B. Y. (2019) · Psychological Medicine · doi:10.1017/s0033291719002277 · Cited by 72
Age-related changes in anterior cingulate cortex glutamate in schizophrenia: A 1H MRS Study at 7Tesla
Brandt, A. S., Unschuld, P. G., Pradhan, S., Lim, I. A. L., Churchill, G., Harris, A. D., Hua, J., Barker, P. B., Ross, C. A., van Zijl, P. C. M., et al. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.02.017 · Cited by 70
The impact of metabotropic glutamate receptors into active neurodegenerative processes: A “dark side” in the development of new symptomatic treatments for neurologic and psychiatric disorders
Bruno, V., Caraci, F., Copani, A., Matrisciano, F., Nicoletti, F., & Battaglia, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.044 · Cited by 73
Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy
Ohrmann, P., Kugel, H., Bauer, J., Siegmund, A., Kölkebeck, K., Suslow, T., Wiedl, K. H., Rothermundt, M., Arolt, V., & Pedersen, A. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.08.005 · Cited by 70
Imaging-Based Neurochemistry in Schizophrenia: A Systematic Review and Implications for Dysfunctional Long-Term Potentiation
Salavati, B., Rajji, T. K., Price, R., Sun, Y., Graff‐Guerrero, A., & Daskalakis, Z. J. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu132 · Cited by 71
Associations Between Cognitive Function and Levels of Glutamatergic Metabolites and Gamma-Aminobutyric Acid in Antipsychotic-Naïve Patients With Schizophrenia or Psychosis
Bojesen, K. B., Broberg, B. V., Fagerlund, B., Jessen, K., Thomas, M. B., Sigvard, A. K., Tangmose, K., Nielsen, M. Ø., Andersen, G. S., Larsson, H. B. W., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.06.027 · Cited by 71
Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies
Schwerk, A. M. K., Alves, F. D. S., Pouwels, P. J. W., & van Amelsvoort, T. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12398 · Cited by 68
Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy
Tandon, N., Bolo, N. R., Sanghavi, K., Mathew, I. T., Francis, A., Stanley, J. A., & Keshavan, M. S. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.05.024 · Cited by 68
Diverse Glial Cell Line-Derived Neurotrophic Factor (GDNF) Support Between Mania and Schizophrenia: A Comparative Study in Four Major Psychiatric Disorders
Tunca, Z., Akdede, B. K., Özerdem, A., Alkın, T., Polat, S., Ceylan, D., Bayın, M., Kocuk, N. C., Şimşek, Ş., Resmi, H., et al. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2014.11.003 · Cited by 66
Lack of progression of brain abnormalities in first-episode psychosis: a longitudinal magnetic resonance imaging study
Schaufelberger, M. S., Lappin, J., Duran, F., Rosa, P. G. P., Uchida, R. R., Santos, L. C., Murray, R. M., McGuire, P. K., Scazufca, M., Menezes, P. R., et al. (2010) · Psychological Medicine · doi:10.1017/s0033291710002163 · Cited by 63
Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation.
Allen, P., Chaddock, C. A., Egerton, A., Howes, O., Barker, G., Bonoldi, I., Fusar-Poli, P., Murray, R., & McGuire, P. (2015) · Schizophrenia bulletin · doi:10.1093/schbul/sbu115 · Cited by 74
Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia: A systematic review and meta-analysis of 1H-MRS studies
Iwata, Y., Nakajima, S., Plitman, E., Mihashi, Y., Caravaggio, F., Chung, J. K., Kim, J., Gerretsen, P., Mimura, M., Remington, G. J., et al. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.016 · Cited by 60
Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update
Bustillo, J. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.3/jbustillo · Cited by 60
Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample
Bustillo, J., Jones, T., Chen, H., Lemke, N. T., Abbott, C., Qualls, C., Stromberg, S. F., Cañive, J. M., & Gasparovic, C. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw122 · Cited by 58
Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity
Plitman, E., Patel, R., Chung, J. K., Pipitone, J., Chavez, S., Reyes-Madrigal, F., Gómez-Cruz, G., León-Ortíz, P., Chakravarty, M. M., de la Fuente‐Sandoval, C., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.84 · Cited by 55
Magnetic Resonance Imaging in Studying Schizophrenia, Negative Symptoms, and the Glutamate System
Gruber, O., Chadha, A. S., & Aach, H. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00032 · Cited by 55
Beyond static measures: A review of functional magnetic resonance spectroscopy and its potential to investigate dynamic glutamatergic abnormalities in schizophrenia
Jelen, L. A., King, S., Mullins, P. G., & Stone, J. M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117747579 · Cited by 54
Proton Magnetic Resonance Spectroscopy of N-acetyl Aspartate in Chronic Schizophrenia, First Episode of Psychosis and High-Risk of Psychosis: A Systematic Review and Meta-Analysis
Whitehurst, T., Osugo, M., Townsend, L., Shatalina, E., Vava, R., Onwordi, E. C., & Howes, O. D. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.10.001 · Cited by 56
Longitudinal Assessment of Gray and White Matter in Chronic Schizophrenia: A Combined Diffusion-Tensor and Structural Magnetic Resonance Imaging Study
Mitelman, S. A., Canfield, E. L., Newmark, R. E., Brickman, A. M., Torosjan, Y., Chu, K.-W., Hazlett, E. A., Haznedar, M. M., Shihabuddin, L., & Buchsbaum, M. S. (2009) · The Open Neuroimaging Journal · doi:10.2174/1874440000903010031 · Cited by 53
Effect of l-theanine on glutamatergic function in patients with schizophrenia
Ota, M., Wakabayashi, C., Sato, N., Hori, H., Hattori, K., Teraishi, T., Ozawa, H., Okubo, T., & Kunugi, H. (2015) · Acta Neuropsychiatrica · doi:10.1017/neu.2015.22 · Cited by 52
Frontale Hirnvolumenminderung durch Antipsychotika?
Aderhold, V., Weinmann, S., Hägele, C., & Heinz, A. (2014) · Der Nervenarzt · doi:10.1007/s00115-014-4027-5 · Cited by 52
Proton MR Spectroscopy–Detectable Major Neurotransmitters of the Brain: Biology and Possible Clinical Applications
Agarwal, N., & Renshaw, P. F. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2587 · Cited by 51
Evaluation of neuron-glia integrity by in vivo proton magnetic resonance spectroscopy: Implications for psychiatric disorders
Xu, H., Zhang, H., Zhang, J., Huang, Q., Shen, Z., & Wu, R. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.09.027 · Cited by 58
Multimodal functional and structural imaging investigations in psychosis research
Schultz, C. C., Fusar‐Poli, P., Wagner, G., Koch, K., Schachtzabel, C., Gruber, O., Sauer, H., & Schlösser, R. G. M. (2012) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-012-0360-5 · Cited by 52
Putative Astroglial Dysfunction in Schizophrenia: A Meta-Analysis of 1H-MRS Studies of Medial Prefrontal Myo-Inositol
Das, T. K., Dey, A., Sabesan, P., Javadzadeh, A., Théberge, J., Raduà, J., & Palaniyappan, L. K. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00438 · Cited by 49
Self-citation
The Glutamate Hypothesis of Schizophrenia: Neuroimaging and Drug Development
Egerton, A., & Stone, J. M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800784961 · Cited by 51
In Vivo Brain Glycine and Glutamate Concentrations in Patients With First-Episode Psychosis Measured by Echo Time–Averaged Proton Magnetic Resonance Spectroscopy at 4T
Kim, S.-Y., Kaufman, M. J., Cohen, B. M., Jensen, J. E., Coyle, J. T., Du, F., & Öngür, D. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.022 · Cited by 47
Dissecting the neurobiology of linguistic disorganisation and impoverishment in schizophrenia
Palaniyappan, L. K. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.08.015 · Cited by 53
Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?
Palaniyappan, L. K., Park, M. T. M., Jeon, P., Limongi, R., Yang, K., Sawa, A., & Théberge, J. (2021) · Antioxidants · doi:10.3390/antiox10111703 · Cited by 58
Self-citation
Glutamatergic dysfunction linked to energy and membrane lipid metabolism in frontal and anterior cingulate cortices of never treated first-episode schizophrenia patients
Smesny, S., Gussew, A., Biesel, N. J., Schack, S., Walther, M., Rzanny, R., Milleit, B., Christian Gaser, B., Sobanski, T., Schultz, C. C., et al. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.07.013 · Cited by 44
A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia
Reid, M. A., White, D. M., Kraguljac, N. V., & Lahti, A. C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2015.12.003 · Cited by 44
The Effects of Antipsychotic Treatment on the Brain of Patients With First-Episode Schizophrenia: A Selective Review of Longitudinal MRI Studies
Yang, C., Tang, J., Liu, N., Li, Y., Xu, M., Sun, H. J., Bo, T., Gong, Q., Cao, H., Zhang, W., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.593703 · Cited by 48
Longitudinal changes in brain metabolites in healthy controls and patients with first episode psychosis: a 7-Tesla MRS study
Wang, M., Barker, P. B., Cascella, N. G., Coughlin, J. M., Nestadt, G., Nucifora, F. C., Sedlak, T. W., Kelly, A., Laurent Younes, B., Geman, D., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-01969-5 · Cited by 44
Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males
Gama, C. S., Salvador, M. M., Andreazza, A. C., Lobato, M. I. R., Berk, M., Kapczinski, F. P., & Belmonte-de-Abreu, P. S. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.01.018 · Cited by 41
Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials
Chang, C.-H., Lin, C., Liu, C., Chen, S.-J., & Lane, H. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120908016 · Cited by 41
Metabolite Alterations in Adults With Schizophrenia, First Degree Relatives, and Healthy Controls: A Multi-Region 7T MRS Study
Wijtenburg, S. A., Wang, M., Korenic, S. A., Chen, S., Barker, P. B., & Rowland, L. M. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.656459 · Cited by 40
Progressive structural brain changes in schizophrenia
Puri, B. K. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.142 · Cited by 40
Reduced connectivity in anterior cingulate cortex as an early predictor for treatment response in drug-naive, first-episode schizophrenia: A global-brain functional connectivity analysis
Li, H., Ou, Y., Liu, F., Chen, J., Zhao, J., Guo, W., & Fan, X. (2019) · Schizophrenia Research · doi:10.1016/j.schres.2019.09.003 · Cited by 37
Remission from antipsychotic treatment in first episode psychosis related to longitudinal changes in brain glutamate
Merritt, K., Pérez‐Iglesias, R., Sendt, K.-V., Arvanitis, A., Jauhar, S., Pepper, F., Barker, G. J., Glenthoj, B. Y., Arango, C., Lewis, S. W., et al. (2019) · Schizophrenia · doi:10.1038/s41537-019-0080-1 · Cited by 36
Social isolation rearing in rats alters plasma tryptophan metabolism and is reversed by sub-chronic clozapine treatment
Möller, M., du Preez, J. L., Emsley, R. A., & Harvey, B. H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.02.021 · Cited by 36
Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration
Egerton, A., Griffiths, K., Casetta, C., Deakin, J. F. W., Drake, R., Howes, O. D., Kassoumeri, L., Khan, S., Lankshear, S., Lees, J., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01508-w · Cited by 37
A Brain‐wide association study of DISC1 genetic variants reveals a relationship with the structure and functional connectivity of the precuneus in schizophrenia
Gong, X., Lu, W., Kendrick, K. M., Pu, W., Wang, C., Li, J., Lu, G., Liu, Z., Liu, H., & Feng, J. (2014) · Human Brain Mapping · doi:10.1002/hbm.22560 · Cited by 36
Emerging Temporal Lobe Dysfunction in People at Clinical High Risk for Psychosis
Allen, P., Moore, H., Corcoran, C., Gilleen, J., Kozhuharova, P., Reichenberg, A., & Malaspina, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00298 · Cited by 35
Apoptotic markers in cultured fibroblasts correlate with brain metabolites and regional brain volume in antipsychotic-naive first-episode schizophrenia and healthy controls
Batalla, A., Bargalló, N., Gassó, P., Molina-Andreu, O., Pareto, D., Mas, S., de la Roca, J. M., Bernardo, M., Lafuente, A., & Parellada, E. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.122 · Cited by 33
Progressive Changes in Glutamate Concentration in Early Stages of Schizophrenia: A Longitudinal 7-Tesla MRS Study
Jeon, P., Limongi, R., Ford, S. D., Mackinley, M., Dempster, K., Théberge, J., & Palaniyappan, L. K. (2020) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgaa072 · Cited by 32
Self-citation
Prefrontal glutamate levels differentiate early phase schizophrenia and methamphetamine addiction: A 1H MRS study at 3Tesla
Crocker, C. E., Bernier, D. C., Hanstock, C. C., Lakusta, B., Purdon, S. E., Seres, P., & Tibbo, P. G. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.05.004 · Cited by 32
Differences in Electric Field Strength between Clinical and Non-Clinical Populations Induced by Prefrontal Tdcs: A Cross-Diagnostic, Individual MRI Based Modeling Study
Mizutani-Tiebel, Y., Takahashi, S., Karali, T., Mezger, E., Bulubas, L., Papazova, I., Dechantsreiter, E., Stoecklein, S., Papazov, B., Thielscher, A., et al. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103011 · Cited by 29
Large-Scale Fusion of Gray Matter and Resting-State Functional MRI Reveals Common and Distinct Biological Markers across the Psychosis Spectrum in the B-SNIP Cohort
Wang, Z., Meda, S. A., Keshavan, M. S., Tamminga, C. A., Sweeney, J. A., Clementz, B. A., Schretlen, D. J., Calhoun, V. D., Lui, S., & Pearlson, G. D. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00174 · Cited by 31

Authors: Théberge, J., Williamson, K. E., Aoyama, N., Drost, D. J., Manchanda, R., Malla, A. K., Northcott, S., Menon, R. S., Neufeld, R. W. J., Rajakumar, N., Pavlosky, W., Densmore, M., Schaefer, B., & Williamson, P. C.
Affiliations: Western University (CA)
McGill University (CA)
St Joseph's Health Care (CA)
Corresponding author: Théberge, Jean
ORCID: Théberge, Jean
Manchanda, Rahul
Malla, Ashok K.
Menon, Ravi S.
Neufeld, Richard W. J.
Rajakumar, Nagalingam
Venue: British Journal of Psychiatry
Publisher: Royal College of Psychiatrists
Published: 2007-10
Volume: 191
Issue: 4
Pages: 325-334
ISSN: 0007-1250 (ISSN-L)
1472-1465
DOI: 10.1192/bjp.bp.106.033670
OpenAlex: W2066003443
Cited by: 185
References: 42
Citations by year: 2026: 1 · 2025: 4 · 2024: 5 · 2023: 4 · 2022: 5 · 2021: 10 · 2020: 8 · 2019: 11 · 2018: 9 · 2017: 12 · 2016: 10 · 2015: 13 · 2014: 16 · 2013: 12 · 2012: 18
FWCI: 5.64
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.cambridge.org/core/terms (unspecified, 3746 d)
Locations: The British Journal of Psychiatry (publishedVersion)
PubMed (publishedVersion)
Funders: Canadian Institutes of Health Research (12078, MT-12078)
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Arts and Humanities › Philosophy › Mental Health and Psychiatry
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: first-episode schizophrenia, gray matter loss, glutamine, thalamus, anterior cingulate cortex, antipsychotic drugs, neurodegeneration, brain volumetric changes, longitudinal brain changes
MeSH terms: Adult, Female, Glutamine, Gyrus Cinguli, Humans, Functional Laterality, Longitudinal Studies, Magnetic Resonance Imaging, Male, Magnetic Resonance Spectroscopy, Schizophrenia, Thalamus, Time Factors, Case-Control Studies, Glutamic Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks